Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Feb 26, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying sudden cardiac death (SCD) and its connection to acute coronary syndrome (ACS), which is a serious heart condition that can lead to heart attacks and other life-threatening issues. The researchers want to understand how certain biological markers, known as exosomes, can help predict the risk of sudden death in patients who experience ACS. By identifying high-risk patients early, doctors hope to improve treatment and potentially save lives.
To participate in this trial, individuals must be at least 18 years old and have experienced sudden clinical symptoms related to heart problems within the last 24 hours. Participants should have a life expectancy of more than three days and must have a proxy (like a family member) sign the consent form on their behalf. Importantly, this study is not for individuals whose deaths were due to accidents, chronic diseases, or other non-cardiac reasons. Those who join the trial can expect to undergo evaluations that help researchers gather information on how to better predict and manage the risks associated with sudden cardiac events.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The death event happens suddenly.
- • Age ≥ 18 years
- • The patient had obvious clinical symptoms 24 hours before treatment
- • Life expectancy exceeds 3 days
- • Proxy of patients signs the informed consent form
- • Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016
- Exclusion Criteria:
- • Death caused by accident, such as trauma, poisoning, etc.
- • Death from accidental or intentional overdose
- • Death from asphyxia
- • Death is caused by chronic disease or terminal illness
- • The patient died naturally
- • Has participated in other clinical studies
- • Immediate family members give up continuing treatment
About The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is a leading academic medical institution in China, renowned for its commitment to advanced healthcare, research, and medical education. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative medical research aimed at improving patient outcomes. With a focus on translational medicine, the institution fosters collaborations between clinicians and researchers to accelerate the development of novel therapies and enhance the understanding of complex diseases. Through its rigorous adherence to ethical standards and regulatory compliance, the hospital is dedicated to advancing medical knowledge and contributing to the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported